Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities

Umme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Instit...

Full description

Bibliographic Details
Main Authors: Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ
Format: Article
Language:English
Published: Dove Medical Press 2020-03-01
Series:International Journal of Nanomedicine
Subjects:
Online Access:https://www.dovepress.com/nanocarrier-based-therapeutics-and-theranostics-drug-delivery-systems--peer-reviewed-article-IJN
_version_ 1818744227987718144
author Ruman U
Fakurazi S
Masarudin MJ
Hussein MZ
author_facet Ruman U
Fakurazi S
Masarudin MJ
Hussein MZ
author_sort Ruman U
collection DOAJ
description Umme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience Universiti, Putra 43400, Malaysia; 3Department of Human Anatomy, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 4Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Selangor 43400, MalaysiaCorrespondence: Mohd Zobir Hussein Email mzobir@upm.edu.myAbstract: The development of therapeutics and theranostic nanodrug delivery systems have posed a challenging task for the current researchers due to the requirement of having various nanocarriers and active agents for better therapy, imaging, and controlled release of drugs efficiently in one platform. The conventional liver cancer chemotherapy has many negative effects such as multiple drug resistance (MDR), high clearance rate, severe side effects, unwanted drug distribution to the specific site of liver cancer and low concentration of drug that finally reaches liver cancer cells. Therefore, it is necessary to develop novel strategies and novel nanocarriers that will carry the drug molecules specific to the affected cancerous hepatocytes in an adequate amount and duration within the therapeutic window. Therapeutics and theranostic systems have advantages over conventional chemotherapy due to the high efficacy of drug loading or drug encapsulation efficiency, high cellular uptake, high drug release, and minimum side effects. These nanocarriers possess high drug accumulation in the tumor area while minimizing toxic effects on healthy tissues. This review focuses on the current research on nanocarrier-based therapeutics and theranostic drug delivery systems excluding the negative consequences of nanotechnology in the field of drug delivery systems. However, clinical developments of theranostics nanocarriers for liver cancer are considered outside of the scope of this article. This review discusses only the recent developments of nanocarrier-based drug delivery systems for liver cancer therapy and diagnosis. The negative consequences of individual nanocarrier in the drug delivery system will also not be covered in this review.Keywords: nanocarrier, therapeutics, theranostics, drug delivery systems, liver cancer, nanodrug, modalities
first_indexed 2024-12-18T02:40:58Z
format Article
id doaj.art-f2eff56a63f54067bbba38e4ef55e4e2
institution Directory Open Access Journal
issn 1178-2013
language English
last_indexed 2024-12-18T02:40:58Z
publishDate 2020-03-01
publisher Dove Medical Press
record_format Article
series International Journal of Nanomedicine
spelling doaj.art-f2eff56a63f54067bbba38e4ef55e4e22022-12-21T21:23:41ZengDove Medical PressInternational Journal of Nanomedicine1178-20132020-03-01Volume 151437145652211Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug ModalitiesRuman UFakurazi SMasarudin MJHussein MZUmme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience Universiti, Putra 43400, Malaysia; 3Department of Human Anatomy, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 4Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Selangor 43400, MalaysiaCorrespondence: Mohd Zobir Hussein Email mzobir@upm.edu.myAbstract: The development of therapeutics and theranostic nanodrug delivery systems have posed a challenging task for the current researchers due to the requirement of having various nanocarriers and active agents for better therapy, imaging, and controlled release of drugs efficiently in one platform. The conventional liver cancer chemotherapy has many negative effects such as multiple drug resistance (MDR), high clearance rate, severe side effects, unwanted drug distribution to the specific site of liver cancer and low concentration of drug that finally reaches liver cancer cells. Therefore, it is necessary to develop novel strategies and novel nanocarriers that will carry the drug molecules specific to the affected cancerous hepatocytes in an adequate amount and duration within the therapeutic window. Therapeutics and theranostic systems have advantages over conventional chemotherapy due to the high efficacy of drug loading or drug encapsulation efficiency, high cellular uptake, high drug release, and minimum side effects. These nanocarriers possess high drug accumulation in the tumor area while minimizing toxic effects on healthy tissues. This review focuses on the current research on nanocarrier-based therapeutics and theranostic drug delivery systems excluding the negative consequences of nanotechnology in the field of drug delivery systems. However, clinical developments of theranostics nanocarriers for liver cancer are considered outside of the scope of this article. This review discusses only the recent developments of nanocarrier-based drug delivery systems for liver cancer therapy and diagnosis. The negative consequences of individual nanocarrier in the drug delivery system will also not be covered in this review.Keywords: nanocarrier, therapeutics, theranostics, drug delivery systems, liver cancer, nanodrug, modalitieshttps://www.dovepress.com/nanocarrier-based-therapeutics-and-theranostics-drug-delivery-systems--peer-reviewed-article-IJNnanocarriertherapeuticstheranosticsdrug delivery systemsliver cancernanodrugmodalities
spellingShingle Ruman U
Fakurazi S
Masarudin MJ
Hussein MZ
Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
International Journal of Nanomedicine
nanocarrier
therapeutics
theranostics
drug delivery systems
liver cancer
nanodrug
modalities
title Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_full Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_fullStr Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_full_unstemmed Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_short Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_sort nanocarrier based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities
topic nanocarrier
therapeutics
theranostics
drug delivery systems
liver cancer
nanodrug
modalities
url https://www.dovepress.com/nanocarrier-based-therapeutics-and-theranostics-drug-delivery-systems--peer-reviewed-article-IJN
work_keys_str_mv AT rumanu nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities
AT fakurazis nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities
AT masarudinmj nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities
AT husseinmz nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities